Posts tagged immune system
Checkpoint targeting registration studies by end of 2018

Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and lead immuno-oncology (IO) agent, CK-301.

Read More
Arbutus taking multi-faceted approach to HBV

Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with hepatitis B virus.

Read More
In conversation with Dr. Chad Larson

As an advisor and consultant with Cyrex Laboratories, a clinical immunology lab, Dr. Chad Larson holds a Doctor of Naturopathic Medicine degree from Southwest College of Naturopathic Medicine and a Doctor of Chiropractic degree from Southern California University of Health Sciences. 

Read More
Enumeral pursuing near-term collaborations

Wael Fayad, who moved into the executive suite of Enumeral (OTCQB:ENUM) as chairman, president and CEO at the end of September, plans to reboot the company in the near term through partnering and collaborations.

Read More
William Blair analyst discusses Hep B space

As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the U.S., and No. 2 for stock-picking in biotech in 2011. She also received the No. 2 ranking in The Wall Street Journal’s “Best on the Street” listing in 2011. Prior to joining William Blair in 2011, Ms. Xu was a SVP and senior biotech analyst at Wedbush Securities; VP and senior biotech analyst at Credit Suisse; and a senior biotech analyst at Pacific Growth Equities. Before her move into equity research, Ms. Xu worked in investment banking for two years. In this interview with, Ms. Xu discusses her industry-leading research report entitled, Hepatitis B: The Next Frontier, and some of her best investment ideas in the Hep B space.

Read More
Lupus Foundation puzzled by negative reaction to Aurinia data

As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of directors and the lupus research community to bring national attention and resources to lupus research and education. Ms. Raymond came to the LFA after serving as the founding CEO of the National Osteoporosis Foundation, beginning in 1986. She envisions great progress in lupus treatment and care over the next 10 years but recognizes the urgent need to elevate lupus on the national healthcare agenda by increasing federal and private investment in research on lupus and developing constructive public policies aimed at bringing support and services to all people affected by lupus. In this interview with, Ms. Raymond discusses the state of the disease and results of a recent clinical study by Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP).

Read More
FeatureLeonard ZehrThe Lupus Foundation of America, LFA, Sandra Raymond, lupus research community, National Osteoporosis Foundation, lupus treatment, national health care, Aurinia Pharmaceuticals, Aurinia, NASDAQ:AUPH, NASDAQ, AUPH, TSX:AUP, TSX, AUP, autoimmune disease, immune system, healthy tissues, inflammation, organ damage, life-threatening, treatments, joint damage, skin rashes, extreme fatigue, hair loss, kidneys, lungs, cardiovascular, brain, disease flares, treatment regimens, mortality, genetics, hormonal factors, environmental triggers, imbalance, bacteria, organ, tissue, sun exposure, lupus, lupus flares, butterfly-shaped rash, cheeks, bridge of the nose, organ systems, mortality statistics, renal disease, cardiovascular disease, infections, memorial donations, pioneering physicians, steroids, chemotherapies, Benlysta, mouth sores, hyperactive immune system, osteoporosis, bone fractures, insomnia, diabetes, infertility, blood system, nervous system, disorders, breast cancer, breast cancer patients, lupus kidney disease, chemo, tissue damage, kidney disease, lupus nephritis, Phase 2 trial, Phase 3 trial, Aurinia’s voclosporin, scientific literature, Bristol Myers-Squibb’s trial, Abatacept, mycophenolate mofetil, Asia, research initiatives, national and international awareness campaigns, fostered national legislation, education programs, biology, new medications, private sector, FDA, clinical trials, disease activity instrument, questionnaire, global biopharmaceutical company, global movement